Stay updated on Pembrolizumab Ipilimumab Melanoma Immunotherapy Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Ipilimumab Melanoma Immunotherapy Clinical Trial page.

Latest updates to the Pembrolizumab Ipilimumab Melanoma Immunotherapy Clinical Trial page
- Check4 days agoChange DetectedThe webpage has updated its version from v2.16.2 to v2.16.3 and has replaced older dates from May 2024 with new dates in June 2025.SummaryDifference0.9%
- Check11 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check19 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference1%
- Check26 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.2%
- Check48 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check62 days agoChange DetectedThe page has undergone significant changes, including the removal of detailed information about a Phase II study on the combination of pembrolizumab and ipilimumab for advanced melanoma, while adding a new identifier and a revision number.SummaryDifference47%
Stay in the know with updates to Pembrolizumab Ipilimumab Melanoma Immunotherapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Ipilimumab Melanoma Immunotherapy Clinical Trial page.